Assessment of study participants’ neutralizing antibodies at 21 days after the second dose of their vaccine revealed that the 277 without diabetes had approximately 70% neutralization, and the 109 people with diabetes and good glycemic control had around 60% neutralization, which was a nonsignificant difference.

There were also canagliflozin-associated cost savings for heart failure (£ 206 [$ 277; € 227]), myocardial infarction (£ 45 [$ 60; € 50]), and stroke (£ 19 [$ 26; €21]), but Willis et al note that the reduction in these events “was partially offset by increased survival and longer exposure to the risks.”

The DEPICT-1 (Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes) investigators found that insulin-treated patients with inadequately controlled diabetes who were randomly assigned to receive the sodium–glucose cotransporter-2 (SGLT2) inhibitor at a dose of 5 mg (n=277) or 10 mg (n=296) once daily experienced a mean reduction in glycated hemoglobin (HbA1c) levels from 8.5% at the time of randomization to approximately 8.0% at week 24.